High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Infection has emerged as the chief cause of non-relapse mortality (NRM) post CD19-targeting chimeric antigen receptor T-cell therapy (CAR-T) therapy. Even though up to 50% of patients may remain infection-free, many suffer multiple severe, life-threatening, or fatal infectious events. The primary aim of this study was to explore severe and life-threatening infections post licensed CAR-T therapy in large B-cell lymphoma, with a focus on the role of disease burden and disease sites in assessing individual risk. We sought to understand the cohort of patients who experience ≥2 infections and those at the highest risk of infectious NRM. Our analysis identifies a higher disease burden after bridging therapy as associated with infection events. Those developing ≥2 infections emerged as a uniquely high-risk cohort, particularly if the second (or beyond) infection occurred during an episode of immune effector cell-associated neurotoxicity syndrome (ICANS) or while on steroids and/or anakinra for ICANS. Herein, we also describe the first reported cases of “CAR-T cold sepsis,” a phenomenon characterized by the lack of an appreciable systemic inflammatory response at the time of detection of infection. We propose a risk-based strategy to encourage heightened clinician awareness of cold sepsis, with a view to reducing NRM.

References Powered by Scopus

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

4415Citations
N/AReaders
Get full text

Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma

4333Citations
N/AReaders
Get full text

Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification

4074Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The Burden of Invasive Fungal Disease Following Chimeric Antigen Receptor T-Cell Therapy and Strategies for Prevention

12Citations
N/AReaders
Get full text

A Pathologist’s Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products

1Citations
N/AReaders
Get full text

The present and future of CAR T-cell therapy for adult B-cell ALL

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

O’Reilly, M. A., Neill, L., Collin, S. M., Stone, N., Springell, D., Mensah, J., … Sanderson, R. (2024). High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma. HemaSphere, 8(1). https://doi.org/10.1002/hem3.29

Readers' Seniority

Tooltip

Researcher 4

67%

PhD / Post grad / Masters / Doc 2

33%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

57%

Nursing and Health Professions 1

14%

Immunology and Microbiology 1

14%

Pharmacology, Toxicology and Pharmaceut... 1

14%

Save time finding and organizing research with Mendeley

Sign up for free